Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 79

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 79
---
holder Approval for five years from Stockholder Approval.

In January 2025, we issued warrants to purchase
up to an aggregate of 408,621 shares of common stock at an exercise price of $3.855 per share. The January 2025 Common Warrants are exercisable
upon issuance and expire twenty-four months from the date of issuance. We issued to the Placement Agent (or its designees) warrants to
purchase up to 15,325 shares of common stock. The January 2025 Placement Agent Warrants have an exercise price equal to $6.382 per share
and are exercisable upon issuance, or January 30, 2025, for twenty-four months from the date of issuance, or January 30, 2027.

On February 5, 2025, we issued warrants to purchase
up to an aggregate of 300,700 shares of common stock at an exercise price of $2.95 per share. The February 2025 Warrants are exercisable
upon issuance and expire twenty-four months from the date of issuance. We issued to the Placement Agent (or its designees) warrants to
purchase up to 22,554 shares of common stock. The February 2025 Placement Agent Warrants have an exercise price equal to $4.469 per share
and are exercisable upon issuance, or February 6, 2025, for twenty-four months from the date of issuance, or February 8, 2027.

The warrants described above were deemed exempt
from registration in reliance on Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance of
securities were made to an accredited investor and did not involve a public offering. The recipients of such securities represented its
intention to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution
thereof.

<div align='center'>II-3</div>

(c) Option Grants.

On July 11, 2023, we granted a total of 632 fully
vested, non-qualified options to purchase shares of common stock at a per share exercise price of $318.00 to the following directors and
in the amounts listed: (i) Stephen Toovey (158 common stock options), (ii) Charles Allen (158 common stock options), (iii) Paul Field
(158 common stock options) and (iv) Cheryl Xu (158 common stock options).

On